Table 3.
The results of SUCRA in the main analysis.
| Treatment | 4-Week healing rate | 8-Week healing rate | ||||
|---|---|---|---|---|---|---|
| SUCRA | PrBest | MeanBank | SUCRA | PrBest | MeanBank | |
| Kev20 | 54.6 | 2.6 | 6.5 | 84.7 | 41.0 | 2.8 |
| Ila10 | 89.3 | 35.8 | 2.3 | 82 | 28.4 | 3.2 |
| Vpz20 | 73.9 | 4.9 | 4.1 | 80.4 | 7.2 | 3.3 |
| Eso40 | 68.6 | 0.3 | 4.8 | 72.5 | 0.7 | 4.3 |
| Vpz40 | 86.7 | 49.8 | 2.6 | 72.7 | 20.7 | 4.3 |
| Pan40 | 45.9 | 0.0 | 7.5 | 56.3 | 0.1 | 6.2 |
| Lan30 | 49.9 | 0.0 | 7.0 | 42 | 0.0 | 8.0 |
| Ome40 | 49.4 | 1.5 | 7.1 | 39.9 | 0.6 | 8.2 |
| Lan60 | 60.0 | 4.7 | 5.8 | 34 | 0.6 | 8.9 |
| Ome20 | 30.9 | 0.0 | 7.5 | 33.3 | 0.0 | 9.0 |
| Rab20 | 25.1 | 0.3 | 10.0 | 26.5 | 0.1 | 9.8 |
| Rab10 | 15.4 | 0.1 | 11.2 | 25.8 | 0.5 | 9.9 |
| Placebo | 0.3 | 0.0 | 13.0 | 0.0 | 0.0 | 13.0 |
Eso40, Esomeprazole 40 mg qd; Fex40, Fexuprazan 40 mg qd; Ila10, Ilaprazole 10 mg qd; Kev20, Keverprazan 20 mg qd; Lan30, Lansoprazole 30 mg qd; Lan60, Lansoprazole 60 mg qd; Ome 40, Omeprazole 40 mg qd; Ome 20, Omeprazole 20 mg qd; Pan40, Pantoprazole 40 mg qd; Rab10, Rabeprazole 10 mg bid; Rab20, Rabeprazole 20 mg qd; SUCRA, surface under the cumulative ranking curve; Teg100, Tegoprazan 100 mg qd; Teg50, Tegoprazan 50 mg qd; Vpz20, Vonoprazan 20 mg qd; Vpz40, Vonoprazan 40 mg qd.